drugset / Trial / NCT06827080
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.
Timeline
- Start
- 2025-02-11
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NYMO32 | Other / unclassified | 1110 mbq | — |
| Subject | NYMO32 | Other / unclassified | 1850 mbq | — |
| Subject | NYMO32 | Other / unclassified | 2960 mbq | — |
| Subject | NYMO32 | Other / unclassified | 4810 mbq | — |
| Subject | NYMO32 | Other / unclassified | 7400 mbq | — |